Journal
FUTURE ONCOLOGY
Volume 15, Issue 33, Pages 3861-3876Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2019-0374
Keywords
anticancer delivery vehicle; Bifidobacterium spp.; bioconversion; gene therapy; targeted-drug delivery system
Categories
Ask authors/readers for more resources
Selective delivery of therapeutic agents into solid tumors has been a major challenge impeding the achievement of long-term disease remission and cure. The need to develop alternative drug delivery routes to achieve higher drug concentration in tumor tissue, reduce unwanted off-target side effects and thus achieve greater therapeutic efficacy, has resulted in an explosive body of research. Bifidobacterium spp. are anaerobic, nonpathogenic, Gram-positive bacteria, commensal to the human gut that are a possible anticancer drug-delivery vehicle. In this review, we describe Bifidobacterium's microbiology, current clinical applications, overview of the preclinical work investigating Bifidobacterium's potential to deliver anticancer therapy, and review the different strategies used up to date. Finally, we discuss both current challenges and future prospects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available